Sweden, May 23, 2022 /PRNewswire/ -- The
Pennsylvania and Maryland
Departments of Health have granted Immunovia, Inc., the US
subsidiary of Immunovia AB (Nasdaq Stockholm: IMMNOV), Clinical
Laboratory permits, allowing physicians in Pennsylvania and Maryland to order the IMMray™ PanCan-d test
for their patients.
"Many clinicians in Pennsylvania and Maryland have been at the forefront of efforts
to enhance surveillance for pancreatic cancer. We are very happy
that these physicians can now utilize IMMray™ PanCan-d to detect
pancreatic cancer in at-risk patients at stages 1 and 2. With these
permits, we are now able to offer IMMray™ PanCan-d in 48 states,"
says Jeff Borcherding, Chief
Executive Officer of Immunovia, Inc., the US subsidiary of
For more information, please contact:
Acting CEO and President
Senior Director Investor Relations and Corporate
Tel: +46 736 36 35 74
The information was submitted for publication on May 23, 2022, at 08:30 am
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
The following files are available for download:
SOURCE Immunovia AB